What the trial found

NIH highlighted the findings on 29 September; the trial paper appeared on 31 August. In 959 participants, 15- or 25-day courses of nirmatrelvir–ritonavir showed no significant benefit over the ritonavir-plus-placebo control on the main long COVID outcomes studied. These covered cognitive, autonomic and exercise-related symptoms. [1, 2]

What changes

The result narrows expectations for these regimens in these patient groups. It also illustrates why improvement within a treatment group is insufficient: the comparison group matters.

What to keep in mind

This trial does not settle every cause of long COVID, rule out every antiviral strategy or overturn evidence for treatment of acute COVID-19. It is not individual medical advice.

Sources & context

Numbered references link the explanation to its sources. Hypothetical examples and visual metaphors are labelled in the text. Checked 3 October 2026.

  1. NIH: Antiviral drug did not improve long COVID symptoms
  2. RECOVER-VITAL: Randomised phase 2 trial
Our editorial principles · Suggest a correction

KEEP EXPLORING

Why One Radio Signal Still Refuses to Explain ItselfExplore · 3 min readA Planet-Sized Mass Does Not Settle an Object's IdentityPeek · 1 min readPatients Helped an Epilepsy Monitor Learn Its MistakesNewsroom · 2 min read

CURIOUS MINDS, SHARED IDEAS

Join the conversation

What surprised you? Share a thought or a question.

Loading reader responses…

Back to Newsroom